Skip to main content

Table 5 Studies evaluating the significance of anti-CCP titer in patients with undifferentiated arthritis (UA)

From: Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study

Author [ref] Patients, n UA UA duration FU Anti-CCP CCP+ baseline UA outcome Anti-CCP titer significance
Kudo-Tanaka [27] 146 ≥ 2 Sj ≤ 2 yr 1 yr ≥ 5 U/ml no serial assay 17% 12% RA 37% non-RA 41% UA 164 ± 136 RA vs 55 ± 72 non-RA/UA P = 0.017
Guzian [18] 253 (83% RA baseline) ≥ 3 Sj ≤ 1 yr 30 mo. ≥ 20 U/ml serial assay (0.30 mo.) 38% 17% RA No correlation low-high CCP/DAS28, HAQ, erosions
Ursum [31] 545 ≥ 2 Sj ≤ 3 yr 2 yr ≥ 5 U/ml serial assay (0.1 yr) 56% 63% RA baseline or at 1 yr No correlation CCP change/DAS28, HAQ, SHS
Emad [28] 69 ≥ 1 Sj ≤ 1 yr 1 yr ≥ 2.9 U/ml no serial assay 59% 26% RA 6% PsA 41% UA 26% remission Correlation CCP titer/Sj, Tj, ESR, erosions
Bos [30] 147 arthralgia 12 (7-36) mo. median 28 (19-39) mo. median ≥ 5 U/ml no serial assay 34% 7% RA 13% ≥ 4Sj 80% no-arthritis Median 141 arthritis vs 31 U/ml non-arthritis HR = 1.7
Mjaavatten [29] 376 (19% RA baseline) ≥ 1 Sj ≤ 16 wk 1 yr ≥ 25 U/ml no serial assay 16% 46% persistent 54% self-limiting 25-100 OR 4.4 101-250 OR = 9.4 > 250 OR = 14 for persistence
Burr [21] 640 (49% RA baseline) ≥ 2 Sj ≥ 4 wk 5 yr ≥ 5 U/ml serial assay (0.5 yr) 30% 72% RA 28% non-RA Median 1.6 U/ml RA vs 0.8 U/ml non-RA
Present study 192 ≥ 1 Sj ≤ 12 wk 2 yr serial assay (0.6,12,18,24 mo.) 42% 37% RA 30% UA 17% self-limiting 16% non-RA RD Correlation titer/time to RA onset and RA development
  1. RA, rheumatoid arthritis; FU, follow up; Sj, swollen joint; CCP, cyclic citrullinated peptide; Tj, tender joint; DAS28, disease activity score; HAQ, health assessment questionnaire; PsA: psoriatic arthritis; RD, rheumatic disease; SHS, Sharp Heijde Score; ESR, erythrocyte sedimentation rate; HR, hazard ratio; OR, odds ratio.